UCBJY:OTCMKTS
UCB Unsponsored Belgium ADR
114,46 US$
arrow_downward
-0,87%(-1,01) 1D
16 ოქტ, 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJY...
Open
114,95 US$
High
115,28 US$
Low
114,23 US$
Mkt. cap
39,95 მლრდ.
Avg. vol.
53,31 ათ.
Volume
70,57 ათ.
52-wk high
168,76 US$
52-wk low
110,55 US$
Beta
0,57
Shares outstanding
389,01 მლნ.
No. of employees
9 ათ.
Open
114,95 US$
High
115,28 US$
Low
114,23 US$
Mkt. cap
39,95 მლრდ.
Avg. vol.
53,31 ათ.
Volume
70,57 ათ.
52-wk high
168,76 US$
52-wk low
110,55 US$
Beta
0,57
Shares outstanding
389,01 მლნ.
No. of employees
9 ათ.
News stories
From web sources and news partners
ad-hoc-news.de
·
55 წუთის წინ
UCB stock pre-market at EUR 204.05: biopharma group overview
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB Unsponsored Belgium ADR
CEOჟან-კრისტოფ ტელიე
Employees9 ათ.
Founded18 იან. 1928
Headquarters-
SectorPharmaceutical industry
Websiteucb.com